Recombinant Canine IL-6 Protein

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Interleukin-6 (IL-6) is a pleiotropic, alpha -helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression (1-5). Mature canine IL-6 is 187 amino acids (aa) in length and shares 58%, 37%, 39%, and 76% aa sequence identity with human, mouse, rat, and feline IL-6, respectively IL-6. IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha , triggering IL-6 R alpha association with gp130 and gp130 dimerization (6). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (7). Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage (5). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha (5). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alpha is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes (2, 5). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alpha but not from other cytokines that use gp130 as a co-receptor (5, 8). IL-6, along with TNF-alpha and IL-1, drives the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease (1-5). When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis (1, 2, 5). IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise (2). In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells (1, 9).

We have publications tested in 1 confirmed species: Canine.

We have publications tested in 1 application: Bioassay.

Showing Publications 1 - 4 of 4.

Publications using 1609-CL	Applications	Species
M Pelst, C Höbart, H de Rooster, B Devriendt, E Cox Immortalised canine buccal epithelial cells' CXCL8 secretion is affected by allergen extracts, Toll-like receptor ligands, IL-17A and calcitriol Veterinary research, 2022-09-13;53(1):72. 2022-09-13 [PMID: 36100942] (Bioassay, Canine)	Bioassay	Canine
V Konduri, MM Halpert, YC Baig, R Coronado, JR Rodgers, JM Levitt, B Cerroni, S Piscoya, N Wilson, L DiBernardi, Z Omarbekov, L Seelhoff, V Ravi, L Douglass, WK Decker Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma Cancer Gene Ther., 2019-01-23;0(0):. 2019-01-23 [PMID: 30670791] (Bioassay, Canine)	Bioassay	Canine
Bauer TR, Olson EM, Huo Y Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter. Gene Ther., 2011-01-13;18(6):553-9. 2011-01-13 [PMID: 21228879] (Bioassay, Canine)	Bioassay	Canine
Wood MW, Breitschwerdt EB, Gookin JL Autocrine effects of interleukin-6 mediate acute-phase proinflammatory and tissue-reparative transcriptional responses of canine bladder mucosa. Infect. Immun., 2010-11-29;79(2):708-15. 2010-11-29 [PMID: 21115724] (Bioassay, Canine)	Bioassay	Canine

Array 1609-CL

• IL-6 Antibodies
• IL-6 Antibody Pair
• IL-6 ELISA Kits
• IL-6 Lysate
• IL-6 Proteins
• IL-6 ELISAs
• IL-6 Proteins and Enzymes